Ortho-McNeil Pharmaceutical

Ortho-McNeil To Acquire U.S. Rights To AXERT

Ortho-McNeil Pharmaceutical, Inc. is to acquire the U.S. sales and marketing rights to AXERT (almotriptan malate) Tablets, pursuant to a licensing agreement with the drug’s innovator Almirall. AXERT is a prescription medication approved to treat migraine headaches in adults. Completion of the transaction, which is expected to occur during the second quarter of 2003, is Read more about Ortho-McNeil To Acquire U.S. Rights To AXERT[…]


Ciphergen Enters Collaboration With Pfizer

Ciphergen Biosystems, Inc. has entered into a collaboration with Pfizer Inc. designed to discover proteins in serum from rat models as well as to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. “This innovative predictive toxicology study will be carried out through our Biomarker Centers,” commented William Rich, Read more about Ciphergen Enters Collaboration With Pfizer[…]


Virologic Expands Pact With Pfizer

ViroLogic Inc. has signed an expanded agreement with Pfizer Inc. to use ViroLogic’s HIV resistance testing technology for Pfizer’s HIV drug discovery and development programs.ViroLogic said the new pact covers work performed for all of Pfizer’s global research and development sites worldwide. As recommended by the FDA’s antiviral drugs advisory committee, biopharmaceutical companies are using Read more about Virologic Expands Pact With Pfizer[…]

Bentley Extends Collaboration With Pfizer

Bentley Pharmaceuticals, Inc. announced has extended its R&D collaborative agreement with Pfizer Inc. Under the terms of the agreement, Bentley and Pfizer will continue to evaluate certain Pfizer compounds for enhanced delivery. As part of the agreement, Pfizer has access to Bentley’s drug delivery platform through a research license. Pfizer will continue to provide the Read more about Bentley Extends Collaboration With Pfizer[…]